Naslov
Monocyte chemoattractant protein 1 (MCP-1) as possible prognostic biomarker in patients with cerebral ischemic stroke – a pilot study

Autori
Kučić Natalia, Bonifačić David

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Abstract book / Cezmi A. Akdis - Davos, 2013, 139-139

Skup
WORLD IMMUNE REGULATION MEETING-VII

Mjesto i datum
Davos, Švicarska, 13.03.2013. - 16.03.2013

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Monocyte chemoattractant protein 1; biomarker; ischemia; cerebral ischemic stroke

Sažetak
Inflammation following cerebral ischemic stroke (IS) contributes to a secondary brain damage mediated by cytokines and chemokines driven by migration of inflammatory cells to the injured brain tissue. In this study, the possible role of monocyte chemoattractant protein-1 (MCP-1) as prognostic biomarker was investigated in eight patients with IS arranged in two groups (NIHSS ≤12 and >12) at first, third and seventh day, by setting it in correlation to number of monocytes and levels of inflammatory cytokines. Flow cytometry was used to determine the state of secondary imunodepression induced by the CNS injury (CIDS) as well as the kinetic of monocytes’ number in peripheral blood of patients with IS. The concentrations of TNF-alpha and MCP-1 were measured in plasma of IS patients by ELISA-based cytokine multiplex assays. On the third day of IS when CIDS occurred, the number of monocytes, in comparison to healthy subjects, increased 3-fold in patients with IS. MCP-1 plasma levels, following initial increase were transiently synchronous decreased at that time point, showing positive trend elevated toward 7th day. Negative correlation between MCP-1 and monocytes in both group of patient on the third day turns to positive at 7th day. Within this seven-day course of our measurements, no correlation between MCP-1 and TNF-alpha was observed. Comparisons within MCP-1 on 7th day and the outcome (estimated by mRS) 6 months after the IS, indicated that patients in the highest quartile for MCP-1 showed a worse outcome of the disease. Based on the outcome assessment by utilizing the MCP-1 plasma level, our data suggests that MCP-1 can be considered as a prognostic biomarker for clinical purpose, but further investigations are necessary to evaluate this pilot study-data.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti

POVEZANOST RADA